Molecular genetic analysis of BAX and cyclin D1 genes in patients with malignant glioma

REFERENCES

• Apte SS, Mattei MG, Olsen BR. Mapping of the human BAX gene to chromosome 19q13.3—q13.4 and isolation of a novel alterna-tively spliced transcript, BAX delta. Genomics 1995; 26: 592–594
   PubMed Web of Science ®Google Scholar
• Bast BT, Pogrel MA, Regezi JA. The expression of apoptotic proteins and matrix met alloproteinases in odontogenic myxomas. J Oral Maxillofac Surg 2003; 61: 1463–1466
   PubMed Web of Science ®Google Scholar
• Biggin A, Henke R, Bennetts B, et al. Mutation screening of the mitochondrial genome using denaturing high performance liquid chromatography. Mol Genet Metab 2005; 84: 61–74
   PubMed Web of Science ®Google Scholar
• Brimmell M, Mendiola R, Mangion J, et al. BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene 1998; 16: 1803–1812
   PubMed Web of Science ®Google Scholar
• Cartron PF, Oliver L, Martin S, et al. The expression of a new variant of the pro-apoptotic molecule Bax, Baxpsi, is correlated with an increased survival of glioblastoma multiforme patients. Hum Mol Genet 2002; 11: 675–687
   PubMed Web of Science ®Google Scholar
• Cheung TH, Yu MMY, Lo KWK, et al. Alteration of cyclin D1 and CDK4 gene in carcinoma of uterine cervix. Cancer Lett 2001; 166: 199–206
   PubMed Web of Science ®Google Scholar
• Colella G, Vikhanskaya F, Codegoni AM, et al. hMLH1 and hMSH2 expression and BAX frameshift mutations in ovarian cancer cell lines and tumors. Carcinogenesis 1998; 19: 691–694
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C. Mutation of cell cycle regulators. Am I Pathol 1995; 147: 545–560
   PubMed Web of Science ®Google Scholar
• Ewen ME, Lamb J. The activities of cyclin D1 that drive tumorigenesis. Trends Mol Med 2004; 10: 158–162
   PubMed Web of Science ®Google Scholar
• Friess H, Lu Z, Graber HU, et al. Bax, but not bc1-2, influences the prognosis of human pancreatic cancer. Gut 1998; 43: 414–421
   PubMed Web of Science ®Google Scholar
• Gema MB, Rodriquez-Parales S, Sanchez-Estevez C, et al. Cyclin D1 gene mutation in endometrial cancer. Oncogenomics 2003; 22: 6115–6118
   PubMed Web of Science ®Google Scholar
• Gil J, Yamamoto H, Zapata JM, et al. Impairment of the proapoptotic activity of Bax by missense mutations found in gastrointestinal cancers. Cancer Res 1999; 59: 2034–2037
   PubMed Web of Science ®Google Scholar
• Jeon YT, Kima JW, Song JH, et al. Cycl in D1 G870A polymorphism and squamous cell carcinoma of the uterine cervix in Korean women. Cancer Lett 2005; 223: 259–263
   PubMed Web of Science ®Google Scholar
• Kleihues P, Burger PC, Scheithauer BW. Histological Typing of Tumours of the Central Nervous System, Berlin: Springer-Verlag, 1993
   Google Scholar
• Kong S, Amos CI, Luthra R, et al. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis color-ectal cancer. Cancer Res 2000; 60: 249–252
   PubMed Web of Science ®Google Scholar
• Krajewski S, Blomqvist C, Franssila K, et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55: 4471–4478
   PubMed Web of Science ®Google Scholar
• Lim G, Halimah Y, eds. Second Report of the National Cancer Registry. Cancer Incidence in Malaysia 2003, Kuala Lumpur: National Cancer Registry, 2004
   Google Scholar
• Liou AK, Clark RS, Henshall DC, et al. To die or not to die for neurons in ischemia, traumatic brain injury and epilepsy: A review on the stress-activated signaling pathways and apoptotic pathways. Prog Neurobiol 2003; 69: 103–142
   PubMed Web of Science ®Google Scholar
• Mackey TJ, Borkowski A, Amin P, et al. bc1-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 1998; 52: 1085–1090
   PubMed Web of Science ®Google Scholar
• McPake CR, Tillman DM, Poquette CA, et al. Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of BcI-2 expression and p53 status. Oncol Res 1998; 10: 235–244
   PubMed Web of Science ®Google Scholar
• Meijerink JP, Mensink EJ, Wang K, et al. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 1998; 91: 2991–2997
   PubMed Web of Science ®Google Scholar
• Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293–299
   PubMed Web of Science ®Google Scholar
• Monteiro E, Varzim G, Pires AM, et al. Cyclin D1 A870G polymorphism and amplification in laryngeal squamous cell carcinoma: Implications of tumor localization and tobacco exposure. Cancer Detect Prey 2004; 28: 237–243
   PubMedGoogle Scholar
• Nakata B, Muguruma K, Hirakawa K, et al. Predictive value of BcI-2 and Bax protein expression for chemotherapeutic effect in gastric cancer. A pilot study. Oncology 1998; 55: 543–547
   PubMed Web of Science ®Google Scholar
• Nishimoto IN, Pinheiro NA, Rogatto SR, et al. Cyclin D1 gene polymorphism as a risk factor for squamous cell carcinoma of the upper aerodigestive system in non-alcoholics. Oral Oncol 2004; 40: 604–610
   PubMed Web of Science ®Google Scholar
• Ouyang H, Furukawa T, Abe T, et al. The BAX gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium. Clin Cancer Res 1998; 4: 1071–1074
   PubMed Web of Science ®Google Scholar
• Pepper C, Hoy T, Bentley P. Elevated BcI-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance. Leuk Lymphoma 1998; 28: 355–361
   PubMed Web of Science ®Google Scholar
• Rampino N, Yamamoto H, lonov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997; 275: 967–969
   PubMed Web of Science ®Google Scholar
• Rousseau A, Lim MS, Lin Z, et al. Frequent cyclin D1 gene amplification and protein overexpression in oral epithelial dysplasias. Oral Oncol 2001; 30: 268–275
   Google Scholar
• Sakuragi N, Salah-eldin AE, Watari H, et al. Bax, BcI-2, and p53 expression in endometrial cancer. Gynecol Oncol 2002; 86: 288–296
   PubMed Web of Science ®Google Scholar
• Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672–1677
   PubMed Web of Science ®Google Scholar
• Sundarrajan M, Gupta S, Rao KVK. Overexpression of cyclin D1 is associated with the decondensation of chromatin during DEN-induced sequential hepatocarcinogenesis. Cell Biol Int 2002; 26: 699–706
   PubMed Web of Science ®Google Scholar
• Yagi OK, Akiyama Y, Nomizu T, et al. Proapoptotic gene BAX is frequently mutated in hereditary nonpolyposis colorectal cancers but not in adenomas. Gastroenterology 1998; 114: 268–274
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Sawai H, Perucho M. Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res 1997; 57: 4420–4426
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Sawai H, Weber TK, et al. Somatic frameshift mutations in DNA mismatch repair and proapoptosis genes in hereditary nonpolyposis colorectal cancer. Cancer Res 1998; 58: 997–1003
   PubMed Web of Science ®Google Scholar
• Yin C, Knudson CM, Korsmeyer Si, et al. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997; 385: 637–640
   PubMed Web of Science ®Google Scholar